Early-stage drug discovery

This service supports early-stage drug discovery by providing a comprehensive and fully integrated platform for target validation, hit-to-lead optimization, and preclinical candidate selection. Tailored to the needs of pharmaceutical companies, biotechnology firms, and research institutions, it is designed to accelerate discovery timelines and enhance decision-making through cutting-edge science and data-driven insights. The project duration is flexible—ranging from a few months to over a year—depending on the project’s scope, stage, and complexity. The overarching goal is to identify and refine promising therapeutic candidates by combining advanced screening technologies, custom assay development, and structure–activity relationship (SAR) studies into a coherent, iterative workflow. Core activities include high-throughput screening, lead identification, and lead optimization, supported by a multidisciplinary team of experts in medicinal chemistry, translational scientists, quality control, and bioinformatics. This integrated expertise ensures a seamless transition from discovery to preclinical evaluation, with continuous scientific and strategic guidance. Expected outcomes include the delivery of optimized preclinical candidates, validated through robust experimental and computational data packages that support informed go/no-go decisions and facilitate progression to IND-enabling studies. Each project is customized to meet specific client objectives, ensuring scientific excellence, operational flexibility, and a clear, evidence-based path toward clinical development.